[Influence of cytostatic therapy on the immunologic reactivity of patients with chronic polyarthritis].
D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000276:immunology*; D001379:Azathioprine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D005021:Ethylamines / Q000627:therapeutic use; D006801:Humans; D007111:Immunity, Cellular; D007165:Immunosuppression Therapy; D015122:Mercaptopurine / Q000627:therapeutic use; D010078:Oxazines / Q000627:therapeutic use; D017976:Phosphorus Acids / Q000627:therapeutic use; D012882:Skin Tests
D000970:Antineoplastic Agents; D005021:Ethylamines; D010078:Oxazines; D017976:Phosphorus Acids; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001379:Azathioprine
Der Einfluss cytostatischer Therapie auf die immunologische Reaktionsfähigkeit von Patienten mit chronischer Polyarthritis.